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Rotavirus (RV) is considered to be the most common cause of gastroenteritis among
infants aged less than 5 years old. Human milk bioactive compounds have the
ability to modulate the diarrheic process caused by several intestinal pathogens.
This study aimed to evaluate the potential protective role of a specific human
milk oligosaccharide, 2′-fucosyllactose (2′-FL), a mixture of the prebiotic short-chain
galacto-oligosaccharides and long-chain fructo-oligosaccharides 9:1 (GOS/FOS) and
their combination (2′-FL+GOS/FOS) on RV-induced diarrhea in suckling rats. The
nutritional intervention was performed from the second to the sixteenth day of life by
oral gavage and on day 5 an RV strain was orally administered to induce infection.
Fecal samples were scored daily to assess the clinical pattern of severity, incidence and
duration of diarrhea. Blood and tissues were obtained at day 8 and 16 in order to evaluate
the effects on the epithelial barrier and the mucosal and systemic immune responses. In
the assessment of severity, incidence and duration of diarrhea, both 2′-FL and GOS/FOS
displayed a beneficial effect in terms of amelioration. However, the mechanisms involved
seemed to differ: 2′-FL displayed a direct ability to promote intestinal maturation and
to enhance neonatal immune responses, while GOS/FOS induced an intestinal trophic
effect and an RV-blocking action. The combination of 2′-FL and GOS/FOS showed
additive effects in some variables. Therefore, it could be a good strategy to add these
compounds in combination to infant formulas, to protect against human RV-induced
diarrhea in children.
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INTRODUCTION
Human milk provides several bioactive factors that benefit the relatively immature immune system
of neonates early in life. These components have been categorized into two different groups
according to either their protective role or their ability to promote maturation (Lewis et al., 2017).
In this sense, humanmilk oligosaccharides (HMOs) are considered to play a part both in protection
and maturation.
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Most of the 200 types of HMOs discovered exhibit a lactose,
polylactosamine or lacto-N-biose core, which is bound to either
fucose or sialic acids. This structure confers on them a high
chemical variability and protection from digestion. Therefore,
the majority of HMOs are neither absorbed nor metabolized in
the proximal gut and reach the distal gut undigested to exert
prebiotic effects on certain bacterial populations, to reinforce
the intestinal barrier and to protect against enteropathogen
infections (Licht et al., 2012; Valcheva and Dieleman, 2016; Barko
et al., 2018). HMOs are present in humanmilk in a relatively high
proportion (5–20 g/L). Their abundance changes over the course
of lactation and their profile is highly variable among women
because their structural diversity depends, inter alia, on genetic
and geographical factors (Kulinich and Liu, 2016; McGuire
et al., 2017). In contrast, the concentration of oligosaccharides in
bovine milk, which is the basis of most infant formula, is 100- to
1000-fold lower than in human milk (Bode, 2015).
The production of single synthetic HMOs is increasingly
becoming available for commercial purposes as their addition
to infant formulas seems to be safe and beneficial for human
infants and even for certain medical disorders (Donovan and
Comstock, 2016; Xiao et al., 2017). The most abundant HMO
is 2′-fucosyllactose (2′-FL), representing ∼30% of the total
oligosaccharides in human milk (He et al., 2016a). In vitro and
in vivo studies with 2′-FL have evidenced its immunomodulatory
effects, which include promoting Th2 and anti-inflammatory
activities (He et al., 2016b), the inhibition of the colonization of
pathogens (Ruiz-Palacios et al., 2003; Weichert et al., 2016; Yu
et al., 2016) and an enhancement of cognitive abilities in rodents
(Vázquez et al., 2015). Moreover, with the aim of mimicking the
composition of human milk, a few clinical studies have tested
the potential beneficial effects of feeding infants with a formula
containing 2′-FL. The addition of 2′-FL was safe, well tolerated,
the growth was comparable to breastfed infants (Marriage et al.,
2015; Puccio et al., 2017) and it modified innate and adaptive
immune profiles to be more like those of babies fed with human
milk (Goehring et al., 2016). However, although 2′-FL has not
proven a prebiotic function yet, it seems to be a good candidate
(Gibson et al., 2017). Oligosaccharides with a proven prebiotic
function are included in infant formulas. The addition of a
mixture of short-chain galacto-oligosaccharides (scGOS) and
long-chain fructo-oligosaccharides (lcFOS) at a 9:1 ratio in infant
formulas has demonstrated multiple health-promoting effects: a
reduction in the incidence of infections (Arslanoglu et al., 2007;
Bruzzese et al., 2009), the modulation of the immune response
(Bakker-Zierikzee et al., 2006; Vos et al., 2006, 2007; Scholtens
et al., 2008; van Hoffen et al., 2009; Kostadinova et al., 2017) and
changes in the microbiota composition (Scholtens et al., 2008;
Huet et al., 2016).
Rotavirus (RV) is the main causative agent of acute diarrheal
disease in infants, which can lead to dehydration or to more
severe complications and even to death if left untreated
(Hostetler, 2004). As the human RV pathogenesis is still unclear
and RV vaccines are not globally implemented, the modulation
by nutritional interventions with bioactive components is of
interest (Gonzalez-Ochoa et al., 2017). Recent studies have
suggested the possible role of both HMOs and GOS/FOS in
the protection against RV-associated diarrhea (Comstock et al.,
2017; Laucirica et al., 2017; Rigo-Adrover et al., 2017a,b), but
several aspects regarding the mechanism of action involved in
such protection are still a matter of study.
Therefore, the present study aimed to evaluate the activity of
2′-FL, scGOS/lcFOS 9:1 and their combination in modulating
RV-induced diarrhea in a neonatal rat model. Moreover, we also
aimed to further investigate the mechanisms of action involved,
by assessing their effects on the intestinal barrier function and the
gut and systemic immune responses.
MATERIALS AND METHODS
Animals
Fifteen G15 pregnant Lewis rats (LEW/OrlRj) were obtained
from Janvier Labs (Le Genest-saint-Isle, France), individually
housed in cages (2184L Eurostandard Type II L, Tecniplast,
West Chester, PA, USA) with large fibrous particles bedding
and tissue papers as enrichment, monitored daily and allowed
to deliver naturally. The day of birth was registered as day 1 of
life. On day 2, litters were randomly assigned to the experimental
groups and culled to 8 pups per lactating dam, with free access
to maternal milk and rat diet. Dams were given a commercial
diet corresponding to the American Institute of Nutrition 93G
formulation (Reeves et al., 1993; TekladGlobal Diet 2014, Envigo,
Indianapolis, IN, USA) and water ad libitum. Animal handling
was performed during the first hours of the light phase on a
scheduled basis, to avoid the influence of biological rhythms.
After separating all the mothers and keeping the pups in the
home-cage, handling and oral administration was performed.
Afterwards, the dam was reunited with the whole litter. Animals
were housed under controlled conditions of temperature and
humidity in a 12 h light−12 h dark cycle, in a special isolated
room designed and authorized to work under biosecurity level 2
conditions, in the Faculty of Pharmacy and Food Science animal
facility (University of Barcelona, Spain).
All experimental procedures were conducted in accordance
with the institutional guidelines for the care and use of laboratory
animals and were approved by the Ethical Committee for
Animal Experimentation of the University of Barcelona and
the Catalonia Government (CEEA-UB Ref. 74/05 and DAAM
3046, respectively), in full compliance with national legislation
following the EU-Directive 2010/63/EU for the protection of
animals used for scientific purposes.
In order to calculate the sample size, the number of pups
was used as the statistical unit. The number of animals in each
group was established by the Appraising Project Office’s program
from the Universidad Miguel Hernández de Elche (Spain), which
allowed the detection of statistically significant differences among
groups assuming that there was no dropout rate and a type I error
of 0.05 (two-sided). The variables used in the calculation included
the clinical outcomes, such as the severity score. Moreover,
independently of the number of animals obtained before, at least
three litters were required for each group, as previous studies
have demonstrated a remarkable variability between litters (Rigo-
Adrover et al., 2017a). According to the estimation performed, 3
litters of 8 animals per group were sufficient. The final number of
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animals was not affected by the dropouts or outliers, which did
not occur in the present study.
Experimental Design
Upon natural delivery, newborn rats were distributed into
five groups of 24 animals each (3 litters of 8 animals): the
reference (REF) group, rotavirus-infected (RV) group, and 3
rotavirus-infected groups supplemented with: (a) a mixture
of scGOS and lcFOS in a 9:1 ratio (RV+GOS/FOS group);
(b) 2′-FL (RV+2′-FL group); and (c) both scGOS/lcFOS and
2′-FL (RV+GOS/FOS+2′-FL group). All supplementations
were provided by Nutricia Research (Utrecht, The
Netherlands).
Suckling rats were orally administered once daily, as
previously described (Rigo-Adrover et al., 2017b), with
the same normalized volume/body weight of all products
(4.5 µL/g/day), from the second to the sixteenth day
of life, corresponding to the strict lactation period. The
RV+GOS/FOS group was supplemented with 0.8 g of
scGOS/lcFOS/100 g of body weight. The RV+2′-FL group
was supplemented with 0.2 g of 2′-FL/100 g of body weight.
2′-FL was produced by microbial fermentation, with >90%
purity. The RV+GOS/FOS+2′-FL group received both products
at the same doses as when given separately and maintaining
the volume of administration (4.5 µL/g/day). Finally, the REF
and RV groups were administered with a matched volume of
water.
The RV (simian SA-11) was obtained by the Virus Enteric
Group of the University of Barcelona leaded by Dr. A.
Bosch and Dr. R. Pintó under the compliance of the current
principles of GLP (Royal Decree 1369/2000, July 19); the
viruses were propagated in fetal African green monkey kidney
(MA-104) cells and titered as plaque-forming units (PFUs), as
previously described (Pérez-Cano et al., 2007).The virus was
inoculated at day 5 of life (4 × 108 Tissue Culture Infectious
Dose 50 [TCID50]/rat) in all the experimental groups with
the exception of the REF group, which received the same
volume of phosphate-buffered solution (PBS) under the same
conditions.
Body weight was recorded daily throughout the study to
assess weight gain. Half (n = 12) of each group of animals
were sacrificed at day 8, to analyze variables associated with
the peak of diarrhea, and the other half (n = 12 per group)
at day 16, to analyze the effects of the supplementations once
the diarrhea was resolved. Moreover, the naso–anal and tail
lengths were measured to determine the body/tail ratio, the body
mass index (BMI), calculated as body weight/length2 (g/cm2)
and the Lee Index, calculated as (weight0.33/length) x 1000
(g0.33/cm).
Fecal Samples Collection and Clinical
Indices
Fecal sampling was performed once daily throughout the study
(from day 4 to day 16 of life) by gently pressing andmassaging the
abdomen. Fecal samples were stored at−20◦C for the analysis of
RV shedding. Severity of diarrhea was expressed by fecal weight
and by scoring fecal samples from 1 to 4 (diarrhea index [DI])
based on color, texture and amount, as follows: normal feces (1);
soft yellow-green feces (2); totally loose yellow-green feces (3);
high amount of watery feces (4). Scores ≥2 indicate diarrheic
feces, whereas scores <2 indicate absence of diarrhea (Pérez-
Cano et al., 2007). The severity-area under the curve (S-AUC)
during days 5–11, coinciding with the period in which animals
displayed diarrhea, was calculated as a global value of severity.
The maximum severity (MS) was defined as the highest score
during the diarrhea period.
Incidence of diarrhea was expressed by the percentage of
diarrheic animals (%DA), which was based on the percentage of
animals displaying scores of DI≥2 in each group. The incidence-
area under the curve (I-AUC) during days 5–11, coinciding with
the period in which animals displayed diarrhea, was calculated
as a global value of incidence. The maximum incidence (MI)
was defined as the highest %DA during the diarrhea period. The
diarrhea period (DP) was calculated by counting the number of
days in which the animals displayed DI ≥2.
The DI, S-AUC, MS, %DA, I-AUC MI and DP were
normalized (nDI, nS-AUC, nMS, n%DA, nI-AUC, nMI and nDP)
in RV+GOS/FOS and RV+GOS/FOS+2′-FL groups, because
of intrinsic fecal aspects of GOS/FOS supplementation, as
previously described (Rigo-Adrover et al., 2017b). The data
from REF, RV and RV+2′-FL were not normalized, because
no basal effect was observed. The normalization of data was
performed by calculating the mean DI of the timepoints when
there was no active diarrhea in the RV group (e.g., before
the infection, days 4–5, and once the diarrhea is solved,
days 12–17). Finally, the difference between this mean and
the baseline score (DI = 1) was subtracted to all values
of DI. All in all, to ascertain the effects of GOS/FOS and
GOS/FOS+2′-FL on RV infection, only the normalized datamust
be read.
Sample Collection and Processing
At days 8 and 16, half of each litter were intramuscularly
anesthetized with ketamine (90 mg/kg) (Merial Laboratories
S.A., Barcelona, Spain) and xylazine (10 mg/kg) (Bayer A.G.,
Leverkusen, Germany), exsanguinated and their thymus, spleen,
liver and intestines were obtained to record the weight. Two 1 cm
sections of the central part of the small intestine were collected for
histomorphometric and gene expression analysis. The remaining
parts of the intestine were opened lengthwise, cut into 5mm
pieces and incubated with 2mL of PBS in a shaker (10min, 37◦C)
to obtain the gut wash (GW). After centrifugation, supernatants
were stored at−20◦ and−80◦C until alpha-1 antitrypsin (A1AT)
and cytokine analysis, respectively. Plasma was obtained after
blood centrifugation and kept at −20◦C for immunoglobulin
analysis.
Small Intestine Histology
Fixed intestinal tissues corresponding to the peak of RV infection
(day 8) were dehydrated, paraffin-embedded and cut into 5µm
cross sections using a microtome (RM2135, Leica, Wetzlar,
Germany). Subsequently, the sections were mounted on glass
slides and kept until staining with hematoxylin-eosin. Finally,
slides were mounted with coverslips using ProLongTM Gold
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Antifade Mountant (Life Technologies, Carlsbad, CA, USA) and
dried overnight. The observation of the intestinal architecture
was performed using a bright-field microscope (Olympus BX41,
Olympus Corporation, Shinjuku, Tokyo, Japan) at 100x. The
sample size was 6 animals, representative of the three litters
in each experimental group (2 animals/litter). The intestinal
perimeter was calculated by measuring the outer layer of the
intestine. Seven villi were selected randomly in each animal and
the villi height and area were measured. The villi width was
measured at the junction of villi and crypts. The crypts depth
and the villi height/crypts depth ratio were also analyzed. The
statistical analysis was performed with each animal’s mean value
of the variables described above. All morphometric measures
were performed with ImageJ (Image Processing and Analysis in
Java, National Institute of Mental Health, Bethesda, MD, USA).
Fecal SA11 Shedding by Elisa
Fecal samples from day 6 (1 day post-inoculation [DPI]) were
diluted in PBS (10 mg/mL) and homogenized using Pellet Pestles
Cordless Motor (Sigma-Aldrich, Madrid, Spain). Homogenates
were centrifuged (170 g, 5min, 4◦C) and supernatants
were frozen at −20◦C until analysis. SA11 virus particles
were quantified by ELISA, as previously described (Rigo-
Adrover et al., 2017a). Titrated dilutions of inactivated SA11
particles, ranging from 106 to 104/mL, were used as standard
curve.
In vitro Blocking Assay
With the objective of testing the ability of the assayed
oligosaccharides to bind the RV, an in-house in vitro blocking
assay was performed (Rigo-Adrover et al., 2017b). SA11 stock was
diluted with 1% PBS-Tween to reach a concentration of 5 × 104
viral particles/mL, which is the highest concentration previously
found in the feces of infected animals in this model. Starting
from the in vivo-administered concentration, different dilutions
(from 1/2 to 1/16) of GOS/FOS or 2′-FL were preincubated with
the virus at 1/1 ratio for 30min. After that, free, noncoated
viral particles were quantified by ELISA, as described in section
Fecal SA11 shedding by ELISA. In order to demonstrate that
the products were directly binding to virions, a negative control
was used. The products were added to anti-RV Ab coated wells
(without the presence of the virus) and after their incubation
during 30min, the supernatants were removed. At that point,
the standard virus was added. Their levels were not affected with
respect to those in which the product was not added previously,
meaning that the oligosaccharides are not binding to the Ab, at
least in a critical position.
Intestinal Permeability Assay
The quantification of A1AT in the gut wash, as a marker
of intestinal permeability, was performed with the rat
SERPINA1/Alpha 1 Antitrypsin ELISA kit (LifeSpan Biosciences
Inc., Seattle, WA, USA) following the manufacturer’s
instructions. The standard concentrations ranged from 100
to 1.563 ng/mL. Assay sensitivity was 1.56 ng/mL.
Immunoglobulins in Plasma
Plasma concentrations of IgM, IgG1, IgG2a, IgG2b, IgG2c,
and IgA at the end of the nutritional intervention (day 16)
were quantified using ProcartaPlexTM Multiplex immunoassay
(eBioscience, San Diego, CA, USA). In brief, specific color-coded
capture beads were bound to the analyte of interest. After adding
different detection antibodies conjugated to phycoerythrin (PE),
the specific concentration of each analyte was obtained by
MAGPIX R© analyzer (Luminex Corporation, Austin, TX, USA)
at the Scientific and Technological Centers of the University
of Barcelona (CCiT-UB). Assay sensitivity was as follows:
0.02 ng/mL for IgM; 0.78 ng/mL for IgG1; 0.02 ng/mL for IgG2a;
0.11 ng/mL for IgG2b; 0.19 pg/mL for IgG2c and 0.48 pg/mL for
IgA. Anti-RV total and IgM immunoglobulins in plasma were
quantified by ELISA as in previous studies (Rigo-Adrover et al.,
2017b).
Intestinal Cytokines in Gut Wash
Gut wash concentrations of interleukin (IL)-1α, IL-4, IL-6, IL-10,
IL-12p70, interferon (IFN)-γ and tumor necrosis factor (TNF)-
α at both day 8 and 16 of the study were quantified using
ProcartaPlexTM Multiplex immunoassay (eBioscience). In brief,
specific color-coded capture beads were bound to the analyte
of interest. Then, different detection antibodies conjugated to
biotin were added. After incubating with streptavidin-PE, the
specific concentration of each analyte was obtained using a
MAGPIX R© analyzer (Luminex Corporation) at the CCiT-UB.
Assay sensitivity was as follows: 3.5 pg/mL for IL-1α; 0.1
pg/mL for IL-4; 1.9 pg/mL for IL-6; 1.6 pg/mL for IL-10; 5.9
pg/mL for IL-12p70; 0.6 pg/mL for IFN-γ; and 0.4 pg/mL for
TNF-α.
Intestinal Gene Expression by Real-Time
PCR
The central section of the small intestine was homogenized
for 30 s in lysing matrix tubes (MP Biomedicals, Illkirch,
France) using a FastPrep-24 instrument (MP Biomedicals), as
previously described (Camps-Bossacoma et al., 2017). RNA
was isolated with the RNeasy R© Mini Kit (Qiagen, Madrid,
Spain) following the manufacturer’s instructions. RNA purity
and concentration were determined with a NanoPhotometer
(BioNova Scientific S.L., Fremont, CA, USA). Later, cDNA was
obtained in a thermal cycler PTC-100 Programmable Thermal
Controller using TaqMan R© Reverse Transcription Reagents
(Applied Biosystems, AB, Weiterstadt, Germany).
The specific PCR TaqMan R© primers (AB) used to assess
gene expression with real-time PCR (ABI Prism 7900 HT,
AB) were pIgR (Rn00562362_m1, I), Iga (4331348, made
to order), Ifng (Rn00594078_m1, I), Tnf (Rn99999017_m1,
I), Tgfb1 (Rn00572010_m1, I), Il10 (Rn00563409_m1, I),
Il17a (Rn01757168_m1, I), Il22 (Rn01760432_m1, I), Muc2
(Rn01498206_m1, I), Ocln (Rn00580064_m1, I), Cldn2
(Rn02063575_s1, I), Fcgrt (Rn00583712_m1, I, encoding
for FcRn), and Prdm1 (Rn03416161_m1, I, encoding for
Blimp-1). The relative gene expression was normalized with the
housekeeping gene Gusb (Rn00566655_m1, I) using the 2 −11Ct
method (Livak and Schmittgen, 2001). Results are expressed as
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percentage of values of each experimental group normalized to
the mean value obtained for the REF group, which was set at
100%.
Short-Chain Fatty Acids in the Cecal
Content
Short-chain fatty acid (SCFA) quantification in cecal content
from 16-day-old rats was performed by headspace-gas
chromatography-mass spectrometry (HS-GC-MS) at the
GC-MS unit of the CCiT-UB. Samples were acidified in 0.1M
formic acid and homogenized using Pellet Pestles Cordless
Motor (Sigma-Aldrich) to reach a concentration of 200 mg/mL.
Then, 100 µL of the homogenized cecal content was added
to 20 µL of internal standard (2-ethylbutyric 85µM) in a
10mL headspace vial (Agilent, Santa Clara, CA, USA). After
incubating the sample for 20min at 60◦C, 1mL of the headspace
gap was injected by a Triplus HS autosampler (Thermo Fisher
Scientific, Barcelona, Spain) into a TRACE GC Ultra system
(Thermo Fisher Scientific) configured with an inlet split flow of
10 mL/min. The separations were performed using an HP-FFAP
column (25m × 0.2mm I.D × 0.3µm film thickness) (Agilent)
with an injector temperature of 250◦C and an oven temperature
program using two rates: from 80◦C (3min) up to 125◦C at
50◦C/min, and from 125◦C up to 225◦C at 6◦C/min. The carrier
gas was helium with a flow of 1 mL/min and the GC-MS transfer
line temperature was 250◦C. The MS was a DSQII (Thermo
Fisher Scientific), which operated in electron ionization and
selected ion monitoring scanning mode (masses 43, 45, 57,
60, 71, 73, 74, 87, 88, and 116). A 10mM volatile free acid
mix serial dilution (Supelco, Bellefonte, PA, USA) containing
formic, acetic, propionic, isobutyric, butyric, isovaleric, valeric,
isocaproic, caproic and heptanoic acids was used as standard.
All analyses were performed in triplicate. The identification
of each compound was carried out using the spectra obtained
with standard compounds and from the NIST mass spectral
library. The internal standard method of quantification was
used for all the targeted acids with the exception of acetic acid,
the quantification of which was performed by the external
standard method (reduced variability was observed). No relevant
matrix effect was detected. The lower limits of detection (in
µmol/g of feces) were as follows: 0.404 for acetic acid, 0.068
for propionic acid, 0.003 for isobutyric acid, 0.020 for butyric
acid, 0.001 for isovaleric acid, 0.001 for valeric acid, 0.025 for
isocaproic acid, 0.012 for caproic acid and 0.046 for heptanoic
acid.
Statistical Analysis
The Statistical Package for the Social Sciences (SPSS
v22.0) (IBM, Chicago, IL, USA) was used for statistical
analysis. Data was tested for homogeneity of variance and
normality distribution by the Levene’s and Shapiro–Wilk
tests, respectively. When data was homogeneous and had a
normal behavior, conventional one-way ANOVA test followed
by the post hoc Bonferroni was performed. Otherwise, the
nonparametric Kruskal–Wallis test followed by the post hoc
Mann–Whitney U (MWU) test were performed. Finally, the
chi-square test was used to compare frequencies of diarrhea




The RV infection did not produce any significant change in
growth either at the peak of diarrhea (day 8) or at the end of the
study (day 16), as shown by the results in body weight, body/tail
ratio, BMI and Lee Index (Table 1). The group supplemented
with GOS/FOS had a slightly higher body weight at the end of
the study (day 16, p < 0.05), and although none of these growth
changes modified the BMI, some differences were seen in the
body/tail length ratio and the Lee Index. All supplementations
increased the body/tail length ratio compared to REF or RV
at some time point. Moreover, the Lee Index was decreased
exclusively at the peak of diarrhea compared to REF.
With regard to organ weight, no changes were observed
in the relative weight of the thymus and liver (data not
shown), whereas a slight increase in the spleen was found for
RV+GOS/FOS and RV+2′-FL at day 16 (0.53 ± 0.03 and 0.53
± 0.02, respectively) compared with that of RV (0.47 ± 0.02,
p< 0.05). RV and oligosaccharide supplementations changed the
relative small and large intestine weight, which in some cases
had a larger percentage of the total body weight (Table 1). At
day 8, the relative small intestine weight increased in the RV
group (p < 0.05) and it was even higher in the oligosaccharide
groups (p < 0.05), which also showed higher values on day 16
(with the exception of the RV+2′-FL group). These changes for
RV+GOS/FOS and RV+GOS/FOS+2′-FL were also observed in
the large intestine, whereas the RV+2′-FL group showed a lower
large intestine weight.
Histomorphometric Analysis and
Maturation Markers in the Small Intestine
The analysis of the jejunum intestinal architecture was performed
at day 8 (Figure 1), corresponding to the peak of diarrhea and
allowing the observation of changes induced by both the RV
and the nutritional supplementations. In our study, we did not
detect major histological differences due to the RV infection
compared to the REF group (Figure 1A). Specifically, the RV
group did not show visual changes of vacuolization, swelling of
villi tips or constriction of the bases, as reported for other RV
strains (Boshuizen et al., 2003). Moreover, SA11 did not induce
villus atrophy or intestinal swelling, as the villus height, area and
the intestinal perimeter were similar to those of the REF group
(Figure 1B). Nevertheless, the RV group showed an increase
in the villi height/crypts depth ratio (p < 0.05), although no
differences were detected in the absolute measure of villus height
or crypt depth.
The supplementations were able to promote positive changes
in some of the morphometric variables analyzed. All rats
supplemented with any of the oligosaccharides displayed higher
villi height (Figure 1B) and area compared to REF, especially
those groups supplemented with GOS/FOS, whose villi were
more than 30% higher than those of the REF and RV groups
(p < 0.05). No changes were observed in the measure of villi
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TABLE 1 | Growth-associated variables.
REF RV RV+GOS/FOS RV+2′-FL RV+GOS/FOS+2′-FL
Body weight (g)
d8 13.52 ± 0.25 13.60 ± 0.19 14.08 ± 0.17 13.51 ± 0.19 13.67 ± 0.19
d16 31.40 ± 0.89 31.91 ± 0.65 34.16 ± 0.55*# 32.79 ± 0.50 33.53 ± 0.40
Body/tail length ratio
d8 2.14 ± 0.07 2.15 ± 0.03 2.26 ± 0.03*# 2.32 ± 0.03*# 2.22 ± 0.03
d16 1.77 ± 0.02 1.77 ± 0.02 1.92 ± 0.04*# 1.86 ± 0.05 1.84 ± 0.03*
BMI (g/cm2)
d8 0.30 ± 0.01 0.29 ± 0.00 0.29 ± 0.00 0.28 ± 0.01 0.28 ± 0.00
d16 0.35 ± 0.01 0.36 ± 0.00 0.37 ± 0.01 0.37 ± 0.01 0.36 ± 0.00
Lee index (g0.33/cm, x1000)
d8 354.76 ± 3.42 348.80 ± 1.73 345.21 ± 1.34* 343.49 ± 2.46*# 344.52 ± 1.43*
d16 334.44 ± 2.51 335.88 ± 2.41 337.12 ± 3.36 337.93 ± 3.48 332.44 ± 1.26
SI/body (w/w, %)
d8 3.10 ± 0.06 3.35 ± 0.04* 4.56 ± 0.11*# 3.84 ± 0.10*# 4.26 ± 0.10*#
d16 2.88 ± 0.06 2.88 ± 0.06 3.99 ± 0.09*# 3.00 ± 0.07 3.58 ± 0.21*#
LI/body (w/w, %)
d8 0.60 ± 0.01 0.60 ± 0.03 0.68 ± 0.02 0.69 ± 0.03 0.75 ± 0.02*#
d16 1.07 ± 0.03 0.98 ± 0.02* 1.25 ± 0.06*# 0.95 ± 0.07* 1.24 ± 0.05*#
Results are expressed as mean ± S.E.M. (n = 12).
*p < 0.05 compared to REF (by MWU test).
#p < 0.05 compared to RV (by MWU test).
BMI, Body mass index; SI, small intestine ; LI, large intestine; w/w, weight/weight; day 8, d8; day 16, d16.
width in any of the groups. Furthermore, the perimeters of the
intestines of GOS/FOS-supplemented animals were found to be
greater than those in the RV group (p < 0.05), confirming an
intestinal trophic effect for these oligosaccharides (Figure 1B).
The expression of the genes encoding for FcRn and Blimp-1
(Figure 1C), enables the intestinal maturation process in suckling
rats to be established (Arévalo Sureda et al., 2017). Although
the inoculation with RV did not affect Blimp-1, it showed a
trend to reduce the expression of FcRn in the RV-infected
groups, probably indicating an accelerated intestinal maturation
due to the challenge. However, in the RV+GOS/FOS and
RV+GOS/FOS+2′-FL groups, its expression was reduced to
a greater extent compared to RV (p < 0.05), suggesting that
probably GOS/FOS is involved in intestinal maturation. No
differences were found in the expression of Blimp-1 after any of
the supplementations (Figure 1C).
Clinical Variables for the Assessment of
Severity, Incidence and Duration of
Diarrhea
Rats inoculated with RV displayed diarrheic feces from days 6
to 11 of life, the highest score being at day 8 (Figures 2A,B).
Most of the animals in the RV group (21/24, 87.5%) displayed
diarrhea (DI ≥2) at some timepoint, although when calculating
the mean DI day by day its value was lower than 2. As shown in
a previous study using the SA11 RV infection model, GOS/FOS
induced changes in fecal consistency, thereby increasing the
number of feces considered as diarrheic before, during and
after the diarrheic process (Rigo-Adrover et al., 2017b). For
this reason, in order to ascertain the effects of GOS/FOS and
GOS/FOS+2′-FL on RV infection, only the normalized data
must be read (Figures 2B,D). The severity of diarrhea of animals
which received these two supplementations showed a significant
reduction (p < 0.05) at days 7, 8 and 9 (Figure 2B). The
supplementation with 2′-FL did not induce this basal fecal
consistency effect and displayed a trend to reduce the severity of
diarrhea (Figure 2A).
The incidence of diarrhea, calculated as the percentage
of diarrheic animals (%DA), evidenced clearer effects
(Figures 2C,D). The RV group displayed the highest incidence
of diarrhea on day 9, when 55.5% of the animals were scored
DI ≥2. However, all three oligosaccharide supplementations
induced amelioration throughout the entire diarrhea period
(Figure 2C), attaining statistical significance at day 8, when less
than 20% of the animals had symptoms of diarrhea (p < 0.05).
After the normalization of data in the groups supplemented with
GOS/FOS (Figure 2D), the incidence of diarrhea in such groups
was reduced by up to 10% DA in the course of the disease.
Other indicators of severity, incidence and duration of
diarrhea were also calculated (Table 2). Regarding the maximum
severity (MS) of diarrhea, the supplementation with 2′-FL
and 15% compared to that of the RV group (p < 0.05).
The normalized maximum severity (nMS), displayed a milder
score for the GOS/FOS groups, showing a 28–30% reduction
(p < 0.05). The calculation of the severity-area under the curve
(S-AUC) displays the average severity for each group. A clear
tendency to reduce the S-AUC with respect to the RV group was
seen for the supplementation with 2′-FL, with a 22% decrease.
The normalized area under the curve (nS-AUC) was reduced in
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FIGURE 1 | Effect of GOS/FOS, 2′-FL and their combination on histomorphometric variables and the intestinal gene expression of maturation markers at the peak of
diarrhea (day 8). (A) Representative images of histological sections of the jejunum stained with hematoxylin and eosin, 100X. (B) Villi height, villi width, villi area, crypts
depth, villi height/crypts depth ratio and perimeter of the jejunum of suckling rats. (C) Relative gene expression of the maturation markers Pdmr (encoding for Blimp-1)
and Fcgrt (encoding for FcRn) by real-time PCR. The relative gene expression was calculated with respect to REF, which corresponded to 100% of transcription.
Results are expressed as mean ± S.E.M. (n = 4–8). *p < 0.05 compared to REF group; #p < 0.05 compared to RV group (by MWU test).
the animals supplemented with GOS/FOS and GOS/FOS+2′-FL
(45 and 58%, respectively, p < 0.05). Similar results were seen
when calculating incidence indicators. The maximum incidence
(MI) and incidence-area under the curve (I-AUC) were reduced
in all groups compared to the RV group, displaying up to 45%
of amelioration upon 2′-FL supplementation and 80 and 90% for
normalized severity indicators in GOS/FOS and GOS/FOS+2′-
FL, respectively (p < 0.05). Finally, the amelioration was also
found in terms of reducing the diarrhea period (DP), which was
reduced more than 50% due to the supplementations (p < 0.05).
The fecal weight was also measured as an objective severity
variable of the diarrheic process (Figure 2E). Before RV
inoculation (pre-diarrhea period [pre-D], corresponding to days
2–5 of life), animals receiving GOS/FOS and GOS/FOS+2′-FL
had a higher fecal weight compared to both the REF and RV
groups, which is likely to be related to the previously direct
changes reported in the fecal consistency (Rigo-Adrover et al.,
2017b). After infecting with the virus (diarrhea period, [D],
corresponding to days 6–11 of life), the RV group showed an
increased fecal weight (p < 0.05, Figure 2E). The effects of the
supplementations with oligosaccharides were seen at days 6–8,
reducing this increase of fecal weight, although only statistical
differences in the supplementation with 2′-FL were attained
(p < 0.05). This lower fecal weight observed in the 2′-FL group,
was maintained until the end of the diarrhea period (days 9–
11). At the end of the diarrheic process (post-diarrhea period,
[post-D], days 12–16 of life), fecal weights from RV and 2′-FL
were similar to those from REF, while the supplementation with
GOS/FOS and GOS/FOS+2′-FL continued to show higher values
due to the non-pathogenic changes in the fecal consistency.
Viral Shedding and Oligosaccharide
Blocking Activity
The viral shedding in feces (Figure 3A) was determined by ELISA
at 1DPI, which corresponded to the day ofmaximum elimination
(Rigo-Adrover et al., 2017a). The RV group eliminated 2.9 ×
105 RV particles/mg of feces, similar to the group supplemented
with 2′-FL, which eliminated 2.3 × 105 RV particles. However,
the RV particles detected in feces of the groups supplemented
with GOS/FOS and GOS/FOS+2′-FL were drastically decreased
(p < 0.05). In fact, this effect has been previously reported
and could be linked to a GOS/FOS blocking activity, interfering
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FIGURE 2 | Clinical indices of diarrhea. (A,B) The severity of diarrhea is represented with the Diarrhea Index (DI), which is based on scoring fecal samples from 1 to 4
depending on the color, texture and abundance. Scores of DI ≥2 indicate presence of diarrhea, whereas scores < 2 indicate absence of diarrhea. (C,D) The incidence
of diarrhea is represented with the percentage of diarrheic animals (%DA), which is based on the percentage of animals displaying DI scores ≥2 in each group.
(A,C) Data is shown non-normalized or (B,D) normalized for the RV+GOS/FOS and RV+GOS/FOS+2′-FL groups taking into account basal values. (E) The fecal
weight, as an objective indicator of the severity of diarrhea, was calculated as the mean value in the pre-diarrhea, diarrhea and post-diarrhea periods. Results are
expressed as mean ± S.E.M. for severity (n = 3–24, depending on the number of fecal samples obtained each day) and unique values for incidence (derived from all
animals each day). Statistical differences not shown in (A–D). *p < 0.05 compared to REF group; #p < 0.05 compared to RV group (by MWU test).
with the quantification of viral particles by ELISA (Rigo-Adrover
et al., 2017b). In this regard, to assess the binding activity of
GOS/FOS and 2′-FL, an in-house in vitro blocking assay was
performed (Figure 3B). As seen previously for GOS/FOS (Rigo-
Adrover et al., 2017b), there was a dose-dependent inhibition
of RV detection after preincubating with the same mixture of
oligosaccharides, reaching an inhibition of approximately 30–
40%. Moreover, the 2′-FL also showed the blocking activity to
a lesser extent, with up to 10–20% of inhibition. Interestingly,
the combination of both oligosaccharides elicited an additive
blocking activity, as seen by an inhibition of RV detection similar
to the sum of the inhibitions of the two oligosaccharides.
Intestinal Barrier Function
The A1AT levels in the gut wash at day 8 of life (Figure 4A)
were determined to assess the changes in the gut permeability.
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TABLE 2 | Analysis of other variables associated with severity, incidence and duration of diarrhea.
RV RV+GOS/FOS RV+2′-FL RV+GOS/FOS+2′-FL
SEVERITY
MS 2.23 ± 0.07 2.09 ± 0.10 1.88 ± 0.09# 2.01 ± 0.07#
nMS – 1.61 ± 0.10# – 1.55 ± 0.07#
S-AUC 2.85 ± 0.17 3.56 ± 0.31 2.22 ± 0.35 2.94 ± 0.33
nS-AUC – 1.57 ± 0.19# – 1.18 ± 0.21#
INCIDENCE
MI 55.56 52.00 29.17a 43.48
nMI – 12.00# – 13.04#
I-AUC 164.44 169.69 91.67 139.31
nI-AUC – 29.69 – 17.39
DURATION
DP 1.40 ± 0.15 1.84 ± 0.19 0.79 ± 0.16# 1.74 ± 0.20
nDP – 0.32 ± 0.13# – 0.17 ± 0.08#
Results are expressed as mean ± S.E.M. for severity and duration variables (n=12–24 depending on the number of fecal samples obtained each day) and unique values for incidence
variables (derived from all animals each day).
#p < 0.05 compared to RV (by MWU test and Chi Square test); MS, maximum severity; nMS, normalized MS; S-AUC, severity-area under the curve; nS-AUC, normalized S-AUC; MI,
maximum incidence; nMI, normalized MI; I-AUC, incidence-area under the curve; nI-AUC, normalized I-AUC.
ap = 0.08.
FIGURE 3 | Viral shedding and in vitro blocking activity of the oligosaccharides used in this study. (A) The viral shedding in feces was assessed at the peak of viral
elimination, corresponding to day 6. (B) The blocking activity of the oligosaccharides was tested by an in-house in vitro blocking assay using the ELISA technique.
SA11 stock was diluted with PBS-Tween 1% to reach a concentration of 5 × 104 viral particles/mL. Starting from the in vivo-administered concentration, different
dilutions (from 1/2 to 1/16) of GOS/FOS, 2′-FL and GOS/FOS+2′-FL were preincubated with the virus at 1/1 ratio for 30min. Free, non-coated viral particles were
quantified by ELISA. The dotted line represents the addition of the results of the GOS/FOS and 2′-FL analyzed separately. Results are expressed as mean ± S.E.M.
(n = 8 for viral shedding and n = 2 replicates from 2 experiments for the blocking assay). *p < 0.05 compared to REF group; #p < 0.05 compared to RV group (by
MWU test).
The plasma level of A1AT is significantly elevated during
the inflammatory response and can be transported across the
intestinal epithelial layer into the intestinal lumen due to the
increased permeability of the intestinal epithelial barrier (Yang
et al., 2015). The RV group displayed higher levels of A1AT in the
gut wash, but they did not differ statistically from the REF group.
However, the supplementation with 2′-FL and GOS/FOS+2′-FL
reduced the concentration of A1AT in the gut wash compared to
both the RV and REF (p < 0.05), indicating that not only they
were able to prevent the gut permeability disruption induced by
RV, but also promoted an enhanced gut barrier function.
The gene expression of molecules involved in the intestinal
barrier function, such as the tight junctions (TJ) or mucin
was assessed by real-time PCR at day 8 of life (Figure 4B).
The expression of occludin (Ocln) and claudin 2 (Cldn2) were
not altered due to RV infection, yet the supplementations with
GOS/FOS and 2′-FL—but not their combination—raised the
expression of Cldn2 (p < 0.05). Regarding the goblet cell-specific
mucin 2 (Muc2), which is involved in the active defense against
RV infection (Boshuizen et al., 2005), in our study its expression
was increased at day 8 in the RV group (p < 0.05). Such increase
was not found in the groups infected with RV and supplemented
with the oligosaccharides, whose levels were similar to those of
the REF group.
Antibody Production
There is evidence supporting the potential of HMOs to directly
affect immune activity in RV-infected neonates (Comstock et al.,
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FIGURE 4 | Assessment of oligosaccharide supplementation on the intestinal barrier function. The effects on the intestinal barrier function was studied at the peak of
diarrhea (day 8). (A) The alpha-1 antitrypsin (A1AT) concentration in the gut wash was analyzed by ELISA as a measure of the intestinal barrier disruption. (B) Relative
expression of tight junction molecules Cldn2 and Ocln and the mucin Muc2 were quantified by real-time PCR. Relative gene expression was calculated with respect to
REF, which corresponded to 100% of transcription. Results are expressed as mean ± S.E.M. (n = 4–8). *p < 0.05 compared to REF group; #p < 0.05 compared to
RV group (by MWU test).
2017). For this reason, we assessed the levels of antibodies in
the plasma of the suckling rats at the end of the study (day 16,
Table 3). The total and IgM anti-RV antibody levels were not
modified due to SA11 infection, although a tendency to increase
anti-RV IgM in the RV group and in those groups supplemented
with GOS/FOS was observed.
The overall immunoglobulin production was modified in
terms of IgG and IgA but not IgM (Table 3). Specifically, the
RV group increased the total IgG levels, reflected in a threefold
increase in IgG2b (Th1-associated isotype) compared to the REF
group, and a slight decrease of IgG1 (Th2-associated isotype),
which therefore increased the Th1/Th2 immunoglobulin ratio
(p < 0.05). Moreover, the main protective immunoglobulin
in mucosal sites, IgA, was also increased due to the infection
(p < 0.05). The supplementation with the oligosaccharides
partially prevented the changes in the production of IgG and
IgA. On the one hand, animals receiving the oligosaccharides did
not increase the total levels of IgG, although a slight increase in
IgG2b was detected with respect to the REF group. Moreover,
IgG1 levels were also lower, and this to a major extent for
the supplementations with GOS/FOS, in which an increased
Th1/Th2 ratio was seen (p < 0.05). On the other hand, the
IgA production was increased in the RV+GOS/FOS and RV+2′-
FL groups but not with the combination, the levels of which
were similar to those of the REF group. Finally, pIgR and Iga
gene expression in the small intestine was not affected either
by RV infection or by the supplementations (data not shown).
All these results suggest that the supplementations induce a
pattern of immunoglobulins more similar to that of the REF
group, probably indicating that a milder humoral response is
required because other oligosaccharide-dependent mechanisms
of protection are involved.
Cytokine Production
Some changes in a collection of cytokines present in the gut wash
both at day 8 and day 16 were observed (Table 4). At day 8,
corresponding to the peak of diarrhea, the concentration of all
cytokines increased in the RV group (p < 0.05 for IL-6, IL-10,
and IL-12), while the supplementation with GOS/FOS, 2′-FL or
their combination prevented such increases. At the end of the
infection (day 16), both RV and RV+2′-FL groups displayed a
similar concentration of cytokines as the REF group. However,
the RV+GOS/FOS group displayed less IL-1β and IL-10 than the
RV group and the RV+GOS/FOS+2′-FL group showed lower
concentrations for all studied cytokines with the exception of IL-4
(p < 0.05).
With regard to the intestinal gene expression of cytokines
(Figure 5), the RV infection did not modify the expression of the
antiviral cytokine IFN-γ, while the supplementations containing
2′-FL boosted its RNA levels, suggesting a possible role in
the inhibition of the RV dissemination (Bass, 1997). Tnf gene
expression was lower in both GOS/FOS groups with respect to
the REF group (p < 0.05). The infection with RV tripled the
expression of Il10, as seen in all RV-infected groups. Tgfb1 and
Il22 gene expression was similar in all groups and Il17 was not
detected.
Cecal SCFA Production
The main metabolites of oligosaccharide breakdown by microbes
are SCFA, which have well-known health-promoting effects on
the host (Vandenplas et al., 2014; Corzo et al., 2015). The amount
of total SCFA and acetic, propionic, isobutyric, butyric, isovaleric,
valeric, caproic, and heptanoic acids produced in the cecum of
the suckling rats were quantified at the latest time point of the
study, thus allowing the observation of the effects after the 15-day
long oligosaccharide supplementation (Figure 6). The amount
of valeric, caproic and heptanoic acids found were below the
limit of detection. The RV infection reduced the total cecal SCFA
production with a consistent reduction of all SCFA, with the
exception of butyric acid, which was not modified compared to
REF. However, the supplementation with 2′-FL only reduced the
amount of acetic acid (p < 0.05), the levels of all the others
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TABLE 3 | Analysis of the concentration of anti-RV antibodies and the concentration of immunoglobulins in plasma at the end of the study (d16).
REF RV RV+GOS/FOS RV+2′-FL RV+GOS/FOS+2′-FL
Anti-RV antibodies (Arbitrary Units/mL)
Total 35.4 ± 2.7 37.2 ± 3.1 30.4 ± 1.6 35.1 ± 3.3 35.8 ± 3.4
IgM 5.7 ± 0.6 7.4 ± 0.8 7.6 ± 0.4 5.8 ± 0.4 7.0 ± 0.5
Immunoglobulins (µg/mL)
IgM 19.5 ± 0.8 19.1 ± 1.3 21.0 ± 0.8 19.2 ± 0.9 20.7 ± 2.5
IgG 3693.3 ± 180.2 5293.6 ± 695.7* 3851.9 ± 98.0 3779.9 ± 207.8 3295.5 ± 410.0
IgG1 273.6 ± 6.7 191.6 ± 13.2* 133.3 ± 6.8*# 194.1 ± 8.7* 147.1 ± 12.7*#
IgG2a 722.8 ± 17.4 672.2 ± 22.4 664.6 ± 51.2 722.9 ± 42.3 565.9 ± 53.9
IgG2b 1055.8 ± 26.2 3185.4 ± 758.3* 1458.1 ± 50.6*# 1567.3 ± 123.4*# 1298.7 ± 267.2#
IgG2c 1641.0 ± 170.4 1244.4 ± 63.8 1595.9 ± 40.6# 1295.6 ± 110.9 1283.9 ± 81.9
Th1/Th2a 2.7 ± 0.2 5.1 ± 1.0* 3.8 ± 0.3* 3.1 ± 0.2 3.6 ± 0.1*
IgA 63.3 ± 1.5 91.4 ± 7.6* 73.9 ± 1.9* 72.7 ± 2.8*# 58.4 ± 6.3#
Results are expressed as mean ± S.E.M. (n=5–9).
* p<0.05 compared to REF (by MWU test). #p<0.05 compared to RV (by MWU test).
a Th1/Th2 ratio refers to the relationship between IgG2b+IgG2c and IgG1+IgG2a.
TABLE 4 | Analysis of the concentration of intestinal cytokines in the gut wash during the peak of diarrhea (day 8) and at the end of the study (day 16).
REF RV RV+GOS/FOS RV+2′-FL RV+GOS/FOS+2′-FL
IL-1β
d8 232.5 ± 37.3 376.3 ± 69.0 254.8 ± 32.7 204.6 ± 35.1# 220.7 ± 62.7
d16 624.0 ± 116.9 542.0 ± 136.1 307.35 ± 70.8* 515.3 ± 99.6 298.6 ± 84.08*
IL-6
d8 375.6 ± 84.0 708.7 ± 149.5* 473.4 ± 75.7 344.8 ± 80.9# 394.5 ± 127.1
d16 1439.2 ± 293.4 1137.24 ± 268.3 718.7 ± 182.7 1045.0 ± 178.77 686.6 ± 210.2*
IL-4
d8 28.3 ± 5.7 51.8 ± 9.6 34.9 ± 4.9 26.9 ± 5.71 31.0 ± 9.2
d16 88.7 ± 17.7 75.3 ± 16.0 47.2 ± 12.0 67.6 ± 11.1 43.9 ± 12.9
IL-10
d8 916.0 ± 125.2 1407.3 ± 209.7* 951.9 ± 100.3 799.9 ± 145.1# 865.1 ± 223.2
d16 1900.5 ± 288.1 1611.2 ± 315.2 965.4 ± 183.9* 1424.1 ± 191.3 919.2 ± 211.8*
IL-12
d8 1453.4 ± 184.3 2321.5 ± 289.2* 1470.2 ± 115.3 1385.2 ± 232.2# 1434.8 ± 285.9
d16 2773.9 ± 520.8 2464.5 ± 407.8 1394.9 ± 381.6 2359.0 ± 377.3 1363.4 ± 315.9*#
IFN-γ
d8 579.0 ± 118.3 1097.6 ± 213.3 715.3 ± 100.8 541.0 ± 122.3# 603.0 ± 188.6
d16 1972.1 ± 385.9 1589.4 ± 383.2 960.5 ± 231.3 1403.7 ± 225.0 918.1 ± 259.5*
TNF-α
d8 145.0 ± 27.5 251.2 ± 45.5 172.0 ± 25.2 133.4 ± 26.6# 149.9 ± 44.2
d16 418.6 ± 81.1 363.6 ± 86.2 213.3 ± 52.2 314.8 ± 52.4 200.8 ± 56.3*
Results are expressed as mean ± S.E.M. (n = 6).
*p < 0.05 compared to REF (by MWU test).
#p < 0.05 compared to RV (by MWU test).
were similar to those of the REF group or even higher, as in the
case of butyric acid (p < 0.05). With regard to the GOS/FOS
supplementation alone, although it did not modify the total
SCFA or the main SCFA, acetic and propionic acids with respect
to the RV levels, it reduced the proportion of less abundant
acids, such as isobutyric, butyric and isovaleric. Finally, the
combination of GOS/FOS and 2′-FL showed differential effects
to the supplementation of GOS/FOS alone, e.g., decreasing the
total SCFA and propionic acid concentrations in the case of the
RV group (p < 0.05).
DISCUSSION
Human milk fed infants seem to have a lower incidence and
severity of infectious diseases compared to those receiving
infant formula (Stuebe, 2009; Lamberti et al., 2011). Several
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FIGURE 5 | Assessment of cytokine gene expression in the small intestine. Cytokines were quantified in the gut wash by real-time PCR at the peak of diarrhea (day 8).
Relative gene expression was calculated in respect to REF, which corresponded to 100% of transcription. Results are expressed as mean ± S.E.M. (n = 4–8).
*p < 0.05 compared to REF group; #p < 0.05 compared to RV group (by MWU test).
FIGURE 6 | Cecal SCFA composition at the end of the study (day 16). Total SCFA, acetic, propionic, isobutyric, butyric and isovaleric acid production was quantified
by HS-GC-MS. Results are expressed as mean ± S.E.M. (n = 9). *p < 0.05 compared to REF group; #p < 0.05 compared to RV group (by MWU test).
bioactive compounds present in human milk are responsible
for the protection against infections affecting mainly the
gastrointestinal tract, such as the acute gastroenteritis produced
in children primarily by rotavirus (RV). In particular, human
milk oligosaccharides (HMOs) seem to be involved in the
interception of pathogen attachment and to enhance the innate
immune defense, among others (Bode, 2015). Herein, we have
demonstrated for the first time that a purified 2′-FL intervention
in a neonatal rat model of RV acute gastroenteritis reduces the
associated clinical symptoms (i.e., it lowers the incidence, severity
and duration) and that such an effect is related to the 2′-FL direct
ability to promote intestinal maturation and to enhance neonatal
immune responses. Other studies that exist assess the effect of
HMO mixtures during RV infection, and therefore it is difficult
to discern the effects of individual oligosaccharides and their
specific mechanisms of action (Li et al., 2014; Comstock et al.,
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2017).However, it has to be taken into account that, although
2′-FL is the main oligosaccharide in human milk it is present
but not so abundant in rat milk, which is dominated mainly by
3′-sialyllactose (3′-SL).
Moreover, it is the first time to assess the effects of the
combination of 2′-FL and GOS/FOS, which kept those outcomes
found separately for each of the products. Finally, we confirmed
the preventive effect of GOS/FOS in RV diarrhea and its RV-
blocking effect found in previous studies (Rigo-Adrover et al.,
2017a,b) and also bring new data regarding its activity (e.g.,
beneficial histomorphometric changes and immunomodulatory
effects).
In the present work, the RV SA11 induced amoderate diarrhea
at some timepoint in nearly 90% of the infected animals. The
non-supplemented and RV-administered animals influenced the
neonatal immune response by increasing IgG systemic antibody
levels andmodulating the cytokine production during the peak of
infection, as similarly observed in other studies (Fromantin et al.,
1998; Azevedo et al., 2006). Furthermore, the infection caused
alterations in the cecal SCFA profile.
Few studies have addressed the in vivo effects of HMOs on RV
infection (Hester et al., 2013; Li et al., 2014). We have shown that
the supplementation of 2′-FL given to neonatal rats before and
during RV infection induced a clear protective role, significantly
reducing the severity score, the incidence and duration of the
diarrhea and the fecal weight. Because of the intrinsic effect on
fecal consistency induced by GOS/FOS, as reported in previous
studies (Rigo-Adrover et al., 2017b), its protective effect was only
clearly observed after the normalization of data.
In the present study, the day of maximum viral shedding in
the RV group was just 1 day post-RV inoculation, as already
described in this model (Pérez-Cano et al., 2007; Rigo-Adrover
et al., 2017a). Viral shedding was reduced up to 6 times by
the GOS/FOS intervention, most probably due to its ability
to bind to the virus, as it has been previously described as a
mechanism of protection during the infective process (Rigo-
Adrover et al., 2017a). The quantification of the virions by PCR
would allow to confirm this hypothesis, as the quantification of
RV gene copies would not be affected due to the binding with
the product. In contrast, the intervention with 2′-FL did not
reduce the viral shedding, despite a slight blocking of RV was
seen in the in vitro assay, suggesting that virus binding would
not be the main mechanism of action involved, at least for this
RV strain, in ameliorating the diarrhea. In fact an in vitro study
of Laucirica et al. (2017) found that 2′-FL may reduce infectivity,
but in high doses. The ability of the HMOs to inhibit binding
has been described in some experimental approaches studying
different enteropathogens (Ruiz-Palacios et al., 2003; Etzold and
Bode, 2014; Koromyslova et al., 2015; Weichert et al., 2016).
These host–microbe–HMOs interactions can be explained by the
similarities between the glycan motifs found in mammalian cells
and in these types of oligosaccharides, which can truly act as
decoy receptors (Donovan and Comstock, 2016).
Some RV diarrhea animal models, usually using the most
virulent strains, induce serious intestinal malabsorption followed
by fluid loss and dehydration, which ultimately affects body
weight loss (Ciarlet et al., 2002; Jacobi et al., 2013). However, the
RV SA11 strain induced a moderate diarrhea without weight loss.
In this regard, GOS/FOS, but not 2′-FL intervention, promoted
body weight gain at the end of the study regardless of the infective
process. There is not a clear conclusion about the effects of the
products on animal growth, as some studies find differences
(Mezoff et al., 2016; Charbonneau et al., 2017) and some others
not (Lima et al., 2017; Rasmussen et al., 2017; Rigo-Adrover et al.,
2017b). Moreover, 2′-FL did promote the growth of the small
intestine, which had a bigger percentage of the total body weight
after 7 days of supplementation. This intestinal trophic effect
of 2′-FL, which was even more evidenced and persistent in the
GOS/FOS dietary intervention, has also been observed before for
other prebiotic compounds, increasing the weight and promoting
positive changes in the intestinal structure (Macfarlane, 2009;
Rasmussen et al., 2017).
In our study, we did not detect major histological differences
in the intestine during the peak of infection due to the RV.
In fact, the absence of histopathological lesions in this model
has also been reported previously (Guerin-Danan et al., 1998).
Moreover, the lack of a clear barrier disruption could be linked
to the mild diarrhea obtained in this particular model and even
to the RV infective process that could be acting as a maturative
challenge itself (Arévalo Sureda et al., 2017). Independently of the
RV effects, GOS/FOS, but not 2′-FL, increased the villi height,
villi area and the perimeter of the small intestine, which is
in accordance with the observed gut growth-promoting effect.
Several studies support this finding, as it has been shown that
mice fed with 1% GOS diet prevented the villus height decrease
induced by deoxynivalenol in the proximal small intestine
(Akbari et al., 2017). Nevertheless, another study using a FOS
diet did not observe any effect on villus height in growing rats
(Daly and Shirazi-beechey, 2006). Regarding supplementation
with HMOs, it is still unclear whether it affects intestinal
architecture, since some studies found increased villi height in
mice (Mezoff et al., 2016), others found a reduction after 2′-FL
supplementation in preterm piglets (Rasmussen et al., 2017).
The present oligosaccharide interventions seem to be involved
in driving the intestinal cell maturation. In order to establish
the impact of both the RV inoculation and the nutritional
intervention on the intestinal maturation process, the gene
expression of two feasible markers of intestinal maturation in
the neonatal rat were assessed during the peak of infection
(Arévalo Sureda et al., 2017). On the one hand, it is well known
that the neonatal constant fragment receptor (FcRn) mediates
the binding and transfer of IgG across the small intestine
during the suckling period of rats, whereas its expression is
markedly decreased at weaning. On the other hand, although
the expression of B-lymphocyte-induced maturation-protein-1
(Blimp-1) is present throughout all stages of rat life, it seems
that it could act as a nuclear transcription repressor in the
distal small intestine of enterocytes during the suckling period
and lower its expression upon weaning (Arévalo Sureda et al.,
2017). In our study, RV inoculation tended to reduce the gene
expression of FcRn during the peak of infection, suggesting that
probably RV challenge has a direct effect on intestine maturation.
However, after interventional supplementations some significant
differences were observed regarding FcRn but not Blimp-1.
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Animals receiving 2′-FL showed a trend toward lower levels
of FcRn compared to the RV group, while the GOS/FOS
supplementation reduced them significantly, suggesting that
both seem to accelerate the intestinal development process in
neonatal rats.
Another possible mechanism involved in the diarrhea
amelioration could be an improvement in the epithelial barrier
function conferring higher resistance to the infection. Herein, the
higher levels of A1AT found in the RV group gut wash revealed
an RV-induced disruption of the barrier integrity at the peak
of infection. Such an effect was remarkably counteracted by 2′-
FL and partially so in animals supplemented with GOS/FOS.
Despite that, this enhanced barrier effect was not associated with
changes in TJ protein gene expression. However, it is in line with a
study showing that although GOS prevented monolayer integrity
impairment and an acceleration of the TJ assembly in vitro, it
did not affect the mRNA expression of CLDN4, OCLN, ZO1, and
ZO2 (Akbari et al., 2017).
Intestinal mucins play an important role in the innate defense
by limiting and neutralizing invading pathogens such as rotavirus
(Kim and Khan, 2013). In the present study, the RV-stimulated
MUC2 production in the small intestine was probably due
to an attempt to control the infection. Such a response was
prevented in animals supplemented with 2′-FL or GOS/FOS,
which displayed mucin levels similar to those present in REF
animals. Other authors have studied the impact of these types
of prebiotics on mucin production and, for example, a FOS diet
during 12 weeks decreased gene expression ofMUC4 (Lima et al.,
2017), while GOS affected goblet cell function (Bhatia et al.,
2015). Per contra, a 4% HMOs blend supplemented in preterm
pigs did not affect the intestinal gene expression of mucins 1 and
2 (Rasmussen et al., 2017).
Besides the action of 2′-FL and GOS/FOS on the maturing
epithelial barrier, their effect on the developing immunity
of the suckling rats is also of importance. Although some
studies have already demonstrated the immunomodulatory
action of GOS/FOS 9:1 (Rigo-Adrover et al., 2017a,b; Vonk
et al., 2017), very few studies have analyzed the immune-
related outcomes of nutritional interventions testing HMOs
at clinical and preclinical levels. Moreover, most of these
studies are mainly focused on growth and toxicology
(Donovan and Comstock, 2016).
Anti-RV Ig has been found to be a good marker of infection
and protection in previous studies in older animals (Pérez-
Cano et al., 2007, 2008; Rigo-Adrover et al., 2017b). Here we
have demonstrated that there is not a clear specific anti-RV
Ig response due to SA11 infection, probably because of the
immature immune system in early life. Thus, the effect of 2′-FL
and GOS/FOS on the anti-RV immune response could not be
properly assessed here. The total and anti-RV Ab found in all
animals of the study may suggest a transference from their dams
through breast milk. Furthermore, Li et al. (2014) did not find
a modulation of HMOs in terms of total anti-RV IgG in a piglet
model of infection. However, the global analysis of humoral
immunity has shed some light regarding the changes in immune
response due to the infection as well as due to the prebiotic
interventions. Once the infection was resolved (day 16), the RV
group showed higher levels of IgG, involving mainly an increase
in an isotype associated with the Th1 response (IgG2b) and a
decrease in that associated with the Th2 (IgG1). 2′-FL, GOS/FOS
and their combination were able to counteract the IgG2b
increase due to RV by reducing the levels of total IgG to reference
values. These results may indicate that the oligosaccharides
supplementation avoided the active immune response
against the virus, likely due to the exclusion mechanisms
mentioned before (i.e., blocking effect and enhancing barrier
integrity).
Moreover, to determine the effects of RV and
supplementations on the cellular response, the intestinal
levels of cytokine gene expression at the peak of infection (day
8) and their production on both day 8 and day 16 (post-diarrhea
period) were assessed. The RV infection produced significant
increases in both pro-inflammatory/Th1 (IL-12, IL-6) and anti-
inflammatory/Th2 (IL-10) cytokines at the peak of infection, as
found in several rotavirus infection models (Gandhi et al., 2017).
The higher intestinal IL-10 content is in accordance with the
higher gene expression in the intestinal tissue of infected animals
found herein and also in other models of RV infection (Li et al.,
2014). This increase, together with that found forMUC2, appears
to be directed by the host with the aim of counteracting the RV
aggression toward the intestinal tissue. In the present study, 2′-
FL, but not GOS/FOS, was able not only to control much of the
cytokine production boosted by the RV but also to decrease the
secretion of other proinflammatory cytokines (IL-1β, IL-6, IL-12,
IFN-γ, TNFα), suggesting its high immunomodulatory role. In
fact, it is suggested that HMOs, such as 2′-FL, can mimic selectin
ligands and directly bind to immune cells and trigger signaling
pathways that can ultimately affect immune cell populations and
cytokine secretion (Donovan and Comstock, 2016). Specifically,
it has been shown that 2′-FL was able to induce PBMC IL-10
and IFNγ production in vitro under stimulatory conditions
(Donovan and Comstock, 2016); ileocecal-resected mice fed
2′-FL, upregulated distal small intestine immune response genes
(Mezoff et al., 2016); and finally, infants fed with infant formula
with 2′-FL had similar cytokine levels to breastfed infants, which
are lower than those of infant formula-fed infants (Goehring
et al., 2016).
Finally, the effect of RV infection and oligosaccharide
supplement on cecal SCFA was established. Intestinal SCFA
production after prebiotic fermentation decreases pH and
inhibits potentially pathogenic bacteria (Gibson et al., 2005).
Moreover, it is known that SCFA may affect epigenetic gene
regulation in the intestinal mucosa by a change in the histone
acetylation promoted by butyric acid (Sanderson, 2004). Our
results indicated that the reduction in SCFA due to RV infection
was not prevented by the oligosaccharide supplementations,
although some enhancing effect of 2′-FL on butyric acid was
found. The lack of effect on this variable is in line with other
studies in which 12 weeks’ supplementation of FOS in vivo did
not affect acetic and propionic production (Lima et al., 2017).
Some other approaches were negative in finding SCFA differences
due to HMO mixtures or 2′-FL (Donovan and Comstock, 2016;
Rasmussen et al., 2017). Moreover, the higher proportion of
butyric acid found in our study after 2′-FL supplementation
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could be linked to the enhanced barrier integrity (Kau et al.,
2012).
One of the objectives of this study was to ascertain whether
the combination of both prebiotic compounds may induce
more beneficial effects than those given separately. Although
both prebiotics have similar effects on several variables (i.e.,
diarrhea reduction and immune response modulation), each
compound also has differential effects (i.e., GOS/FOS has the
highest blocking effect whereas 2′-FL is the strongest barrier
promoter). The combination of both oligosaccharides presented
all the activities found in each prebiotic separately and even
had an additive effect in some variables. Thus, the combination
is as effective as the supplementation alone regarding some
variables, such as the intestinal trophic effect, the SA11 viral
shedding modulation and the butyric production. However,
several features only attained significant differences or appeared
to be more evident with the combination of GOS/FOS and 2′-
FL. Thus, a clear additive effect is found on the trophic effect
observed on the large intestine on day 8, inducing lower AUC
for severity and incidence, potentiating the in vitro blocking
activity against the virus, counteracting the RV-induced increases
in certain Ig isotypes (IgG2b and IgA), or promoting higher
intestinal maturation by means of inducing lower FcRn gene
expression, among others.
In summary, the RV infection in neonatal rats induces
a diarrhea process that involves the alteration of the
immune response. The preventive daily supplementation of a
scGOS/lcFOS 9:1 prebiotic mixture, 2′-FL (the main HMO found
in human milk), or a combination of both is able to partially
prevent the RV-induced diarrhea in this preclinical model. The
mechanisms involved in such protective action included specific
effects on the two lines of defense: immunomodulation and
enhancement of the intestinal barrier function. An additive effect
of the combination of GOS/FOS with 2′-FL was also found in
several mechanisms. These results indicate that these compounds
in combination could be helpful when added to infant formulas,
to protect against human RV-induced diarrhea in children.
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